New Four-Drug cocktail aims to crush resistant myeloma
NCT ID NCT05896228
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing whether a combination of four drugs—iberdomide, daratumumab, carfilzomib, and dexamethasone—can shrink or prevent the return of multiple myeloma in patients whose cancer has relapsed or stopped responding to prior treatments. About 30 participants will receive the therapy in cycles, and researchers will measure how many achieve a very low level of cancer cells (MRD-negativity) after eight cycles. The study also tracks side effects to see if the combination is safe and tolerable.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- iberdomide, daratumumab, carfilzomib, and dexamethasone
- What this could lead to
- If successful, this combination could offer a new treatment option for patients with multiple myeloma that has returned or not responded to prior therapy, potentially leading to deeper remission.
- What could go wrong
- This is a small, early-phase trial with only 30 participants, so results may not apply to all patients. The drug combination may cause side effects and may not work better than current standard treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Miami
RECRUITINGMiami, Florida, 33136, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered donor cells could outsmart relapsed myeloma
- Can a Triple-Drug cocktail tame resistant myeloma?
- Can a One-Two drug punch beat back Hard-to-Treat myeloma?
- CAR-T breakthroughs come with infection risks – new study aims to decode them
- Double-barreled CAR t therapy takes aim at hard-to-treat myeloma
- Can a drug stop dangerous side effects of new myeloma therapies?